Novo Nordisk A/S with price, financials, news flow, and insider context in one page.
Novo Nordisk A/S is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where NVO sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
This page is structured for research context, not a trade call. It gives you a clean read on where NVO sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 96.82B | 48.56B | 12.05B |
| Q4 2025 | 79.14B | 26.89B | -36.22B |
| Q3 2025 | 74.98B | 20.01B | 30.69B |
| Q2 2025 | 76.86B | 26.5B | 24.37B |
Recent insider transaction detail is not available for this symbol right now.
Prime Day ends tonight. These deals are still worth buying. SFGATEThe Very Best Prime Day Deals We’ve Found (And Counting) The New York TimesAmazon Prime Day may be over, but ...
The attack comes as the United States and Iran are supposed to be engaging in a 60-period of no hostilities as they hold talks to end their war.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Novo Nordisk A/S (NVO) — questions investors ask
What is the current stock price of Novo Nordisk A/S (NVO)?
Novo Nordisk A/S (NVO) is trading at $48.07, up 0.90% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Novo Nordisk A/S's market capitalization?
Novo Nordisk A/S has a market capitalization of about 212.8B, derived from the latest share price and shares outstanding.
When is Novo Nordisk A/S's next earnings date?
Novo Nordisk A/S is next expected to report earnings on Aug 5, 2026. The NVO earnings page tracks the estimate and reporting history.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S trades at a forward price-to-earnings ratio of 14.64 — one measure of how the market is pricing its future earnings.
What is NVO's 52-week trading range?
Over the past 52 weeks, NVO has traded between $35.12 and $71.80.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Novo Nordisk A/S pay a dividend?
Novo Nordisk A/S currently carries a dividend yield of about 100.0%.
What is the analyst price target for NVO?
The mean analyst price target for NVO is $47.26, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This NVO page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.